Dermira (NASDAQ:DERM) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Thursday.
Other equities analysts have also issued reports about the stock. Mizuho lowered shares of Dermira from a “buy” rating to a “neutral” rating in a report on Monday, March 5th. Guggenheim began coverage on shares of Dermira in a report on Tuesday, December 5th. They issued a “buy” rating on the stock. Cantor Fitzgerald set a $20.00 price objective on shares of Dermira and gave the stock a “buy” rating in a report on Monday, March 5th. Leerink Swann upped their price objective on shares of Dermira from $42.00 to $48.00 and gave the stock an “outperform” rating in a report on Wednesday, January 17th. Finally, Cowen set a $25.00 target price on shares of Dermira and gave the stock a “buy” rating in a research note on Monday, March 5th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $32.71.
Dermira (DERM) opened at $10.26 on Thursday. The company has a quick ratio of 5.28, a current ratio of 5.28 and a debt-to-equity ratio of 1.87. Dermira has a fifty-two week low of $8.55 and a fifty-two week high of $36.38. The company has a market cap of $429.09, a P/E ratio of -1.39 and a beta of 0.86.
Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.25) by ($0.09). Dermira had a negative return on equity of 62.07% and a negative net margin of 6,678.29%. The company had revenue of $1.34 million during the quarter, compared to analyst estimates of $1.10 million. research analysts anticipate that Dermira will post -4.66 earnings per share for the current year.
In related news, SVP Christopher M. Griffith sold 18,458 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $27.05, for a total transaction of $499,288.90. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Eugene A. Bauer sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $27.34, for a total transaction of $82,020.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 29,758 shares of company stock worth $810,479. 13.30% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN increased its stake in Dermira by 4.0% during the 3rd quarter. Wells Fargo & Company MN now owns 52,995 shares of the biopharmaceutical company’s stock worth $1,431,000 after buying an additional 2,025 shares during the period. New York State Common Retirement Fund increased its position in shares of Dermira by 4.8% in the 3rd quarter. New York State Common Retirement Fund now owns 49,993 shares of the biopharmaceutical company’s stock valued at $1,350,000 after purchasing an additional 2,308 shares during the last quarter. Quantbot Technologies LP increased its position in shares of Dermira by 75.4% in the 3rd quarter. Quantbot Technologies LP now owns 5,371 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 2,309 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Dermira by 47.7% in the 3rd quarter. SG Americas Securities LLC now owns 8,130 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 2,627 shares during the last quarter. Finally, Swiss National Bank increased its position in shares of Dermira by 5.6% in the 4th quarter. Swiss National Bank now owns 52,600 shares of the biopharmaceutical company’s stock valued at $1,463,000 after purchasing an additional 2,800 shares during the last quarter. 94.93% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/03/15/dermira-derm-stock-rating-upgraded-by-bidaskclub.html.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.